Fennec Pharmaceuticals Inc (TSE:FRX) – Investment analysts at Wedbush raised their FY2019 earnings estimates for Fennec Pharmaceuticals in a note issued to investors on Wednesday, November 13th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of ($0.74) per share for the year, up from their prior forecast of ($1.22). Wedbush also issued estimates for Fennec Pharmaceuticals’ Q4 2019 earnings at ($0.13) EPS, Q1 2020 earnings at ($0.12) EPS, Q2 2020 earnings at ($0.12) EPS, Q3 2020 earnings at ($0.12) EPS, Q4 2020 earnings at $5.23 EPS, FY2020 earnings at $4.87 EPS, FY2021 earnings at $1.11 EPS, FY2022 earnings at $2.04 EPS and FY2023 earnings at $3.18 EPS.
The business’s 50-day moving average is C$6.40 and its 200-day moving average is C$5.80. The firm has a market cap of $116.39 million and a PE ratio of -11.41. Fennec Pharmaceuticals has a 12 month low of C$4.35 and a 12 month high of C$10.00.
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
See Also: Penny Stocks, What You Need To Know
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.